Hansa Biopharma AB expects to report revenue of approximately SEK 54m for Q1 ending March 31, 2024, consisting of SEK 48m in product sales and SEK 6m in revenue recognition primarily related to its agreement with Sarepta Therapeutics, Inc.
Hansa Biopharma AB expects to report revenue of approximately SEK 54m for Q1 ending March 31, 2024, consisting of SEK 48m in product sales and SEK 6m in revenue recognition primarily related to its agreement with Sarepta Therapeutics, Inc.